Vav cre mice

A20^HemKO (Tnfaip3^flox/flox mice crossed with Vav-iCre mice) mice were previously described^{11 (link)}. VAV^Cre/+ mice, CD19^cre/+ mice, LysM^cre/+ mice and IFN-γ^−/− mice were purchased from the Jackson laboratory. CD45.1 congenic animals were purchased from the National Cancer Institute. Mice were maintained under specific pathogen–free conditions and used according to the protocols approved by the Institutional Animal Care and Use Committees (IACUC) of Columbia University Medical Center and University of Maryland School of Medicine.

All mice were bred, housed and handled in the Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility of Cincinnati Children’s Hospital Medical Center (CCHMC). Animal care was in strict compliance with the institutional guidelines established by CCHMC, the Guide for the Care and Use of Animals (National Academy of Sciences 1996), and the Association for Assessment and Accreditation of Laboratory Animal Care International. A20^fl/fl mice were kindly provided by AM (University of California San Francisco) and described elsewhere (29 (link)). A20^fl/fl mice were crossed with Vav-Cre mice (Jackson Laboratory, 008610) or RosaCreER mice (Jackson Laboratory, 008463) for conditional deletion of A20 (A20^fl/fl;Vav-Cre, A20^fl/fl;RosaCreER). Both male and female mice were included in all experiments. BM cells were obtained by crushing the femur, tibia, and pelvic bone, and maintained in Iscove’s MDM (Cellgro, Cat No. 10-016-CV) with 10% fetal bovine serum.

Mice homozygous for the floxed MnSOD allele (i.e. B6.Cg-Sod2^tm1, shorthand MnSOD^L/L) were initially bred to mice expressing Cre-recombinase under the control of the vav promoter (i.e. B6.Cg-Tg-Vav1-iCre^A2Kio/J, shorthand vav-Cre mice, Jackson Laboratories) to create hematopoietic stem cell specific knock-outs of MnSOD [7] (link), [10] (link). These mice were sequentially bred to either an oncogenic model of splenic lymphoma (i.e. B6.Cg-Tg-iMyc^Eμ, shorthand iMyc^+/−) or a conditional tumor suppressor knock-out model of thymic and splenic lymphoma (i.e. FVB.129-Trp53^tm1Brn, shorthand p53^L/L, NCI-Frederick Mouse Repository) [11] (link), [12] (link). In all experiments, littermate controls were used to limit the effects of genetic variation amongst strains. Upon weaning, mice were analyzed by tail DNA to confirm appropriate genotype. Mice were observed until death with no additional challenges. Upon death or illness, all mice were examined by full necropsy and cause of death recorded. Kaplan-Meier with Log-Rank analysis was performed and non-cancer deaths were appropriately censored. Causes of death were compared between groups and analyzed by unpaired two-tail Student's t-test. A p value of less than 0.01 was considered significant. All work was performed under the approval of the Institutional Animal Care and Use Committee at the University of Iowa.

All the experiments were conducted according to the Chinese Guidelines on the Care and Use of Laboratory Animals approved by the Institutional Animal Care and Use Committee at Fujian Medical University (FJMU IACUC 2021-0298).
Gsdmd^−/− mice and Gsdmd^+/+ mice were kindly provided by Prof. Jiahuai Han from Xiamen University. Gsdmd^fl/fl mice and Caspase-11^fl/fl mice were purchased from Cyagen Biosciences. Vav-Cre mice were purchased from Jackson Lab. The Vav-Cre mice was hybridized with Gsdmd^fl/fl mice and Caspase-11^fl/fl mice to generate Vav-Cre Gsdmd^fl/fl mice and Vav-Cre Caspase-11^fl/fl mice, respectively. Genotypes were identified by tail-snip PCR amplification (Supplementary Fig.1).